An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3). - Trial NCT06339060
Access comprehensive clinical trial information for NCT06339060 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ruijin Hospital and is currently Not yet recruiting. The study focuses on Esophageal Cancer. Target enrollment is 356 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ruijin Hospital
Timeline & Enrollment
Phase 3
May 01, 2024
Mar 01, 2028
Primary Outcome
3-year overall survival rate
Summary
Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to
 receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation
 strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control
 group).
 
 The 3-year overall survival rate is the primary outcome.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06339060
Non-Device Trial